On October 22, the Korea Bioprocessing Excellence Awards (KBEA) held by IMAPAC, an internationally renowned consulting firm, announced that GenScript ProBio was awarded the " Bioprocessing Excellence in CDMO Services " for its excellent performance，beating other strong competitors such as Lonza and Wuxi AppTec.
The Korea Bioprocessing Excellence Awards (KBEA) recognizes industry leaders, trend-setters and innovators who are actively exploring and practicing leading technologies in the biopharma field
and accords the highest honor of acknowledgement and appreciation for efforts to facilitate biomanufacturing excellence at enhanced speed, reduced cost, and superior quality all across Korea and the rest of the world. IMAPAC recognizes that GenScript ProBio provides excellence CDMO services to its customers by helping them shorten the time from development to clinical use.
GenScript ProBio’s innovative solutions for antibody drug development include antibody drug discovery, antibody engineering and antibody characterization. In terms of biologics development service, GenScript ProBio has built a regulatory-compliant platform, from stable cell line development to clinical manufacturing services, providing high quality material for IND and clinical trials. GenScript ProBio’s total cell and gene therapy solution covers CMC of plasmid and virus for IND filing as well as clinical and commercial manufacturing. Guided by the principle of "providing the best-in-class quality to and serving the interests of customers", our quality management systems ensures phase-appropriate compliance, data integrity and traceability.
GenScript ProBio CEO Dr. Brian Min attended the online award ceremony and said,“ it’s my great honor to receive this award for Bioprocessing Excellence in CDMO Services on behalf of the company. Having just established our business in Jan 2019, we are a relatively new CDMO, but we are all about ‘ innovation through collaboration’. At GenScript ProBio, we will proactively serve our clients, treat you professionally, and make sure our process is the most efficient one.
Our goal is to provide end-to-end services for biologics development and manufacturing which include both ADD and CGT services. And we are very proud of what we have done in the last 20 months. We have achieved a lot of milestones together with our clients. As we all known, COVID 19 makes 2020 very tough, but we will continue helping customers shorten the timeline for the development of biological drugs from discovery to commercialization, significantly lower R&D costs and build a healthier future. ”